GlassScriptPhysician profile
Sherrill A Fox
NPI 1124034566
$3,960.96
in general payments reported to CMS, 2019-2025
28 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $351 · 2021: $573 · 2022: $1,001 · 2023: $446 · 2024: $615 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $905.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $713.32 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $439.55 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $310.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $226.54 | 2019-2023 | Belsomra, Januvia |
| Glaxosmithkline, LLC. | $217.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $199.70 | 2019-2022 | |
| Amgen INC. | $184.97 | 2019-2025 | Repatha, Otezla, Prolia |
| Allergan, INC. | $106.32 | 2019-2020 | |
| Pfizer INC. | $92.89 | 2019-2024 | |
| Eisai INC. | $87.55 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.04 | 2019-2024 | Entyvio, Trintellix |
| Astellas Pharma US INC | $52.73 | 2025 | Veozah |
| Abbott Laboratories | $50.10 | 2021-2023 | Freestyle Libre |
| Acadia Pharmaceuticals INC | $38.49 | 2023-2025 | Daybue |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.51 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $33.70 | 2019 | |
| Celgene Corporation | $26.51 | 2023 | Reblozyl |
| Dexcom, INC. | $24.78 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.68 | 2022 | |
| Boston Scientific Corporation | $19.71 | 2024 | Watchman Access System |
| Inspire Medical Systems, INC. | $19.32 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $19.24 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $18.06 | 2023 | Abilify Maintena, Rexulti |
| Idorsia Pharmaceuticals US INC | $16.50 | 2023 | Quviviq |
| Optinose US, INC. | $12.03 | 2021 | |
| Organon LLC | $8.40 | 2021-2022 | |
| Corium, LLC | $5.76 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherrill Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.